Navigation Links
Hepatitis B Foundation to Host Annual Crystal Ball Gala
Date:1/14/2014

Doylestown, PA (PRWEB) January 14, 2014

Date: Friday, April 11, 2014

Time: 6 p.m. – 11 p.m.

Location: Warrington Country Club, 1360 Almshouse Road, Warrington, Pa.

Details: The Hepatitis B Foundation, the only national nonprofit organization solely dedicated to finding a cure for hepatitis B and improving the quality of life for those affected worldwide, will host its annual Crystal Ball on Friday, April 11 at Warrington Country Club in Warrington, Pa.

Each year, the Crystal Ball attracts hundreds of leaders from the community, academic institutions, government, health care industry and biotech executives. The gala evening is a fundraiser for the foundation, with all proceeds benefitting its global research, outreach and patient advocacy programs.

This year’s event, the “Cherry Blossom Extravaganza,” includes an evening of dinner, dancing, a silent auction and awards ceremony. The Foundation will honor Dr. Thomas Starzl with the 2014 Baruch S. Blumberg Prize for pioneering the first human liver transplant in 1963.

Foundation leaders also will announce the recipients of the 2014 Community Commitment Award, Teri and Jim Holton, of Doylestown. Both have provided generous support to the Hepatitis B Foundation with Teri serving as chair of the Crystal Ball auction committee for the past four years and making it a tremendous success. In addition, Teri volunteers regularly in the community and her church and Jim supports many local food pantries with donations from Kellogg where he is a senior vice president.

The Hepatitis B Foundation is accepting auction items and sponsorship opportunities are still available. For more information regarding the Crystal Ball, call 215-489-4900.

About the Hepatitis B Foundation: Headquartered in Doylestown, Pa., the Hepatitis B Foundation is the only national nonprofit organization solely dedicated to finding a cure for hepatitis B and improving the quality of life for those affected worldwide through research, education and patient advocacy. To learn more, go to http://www.hepb.org, read our blog at http://wp.hepb.org, follow us on Twitter @HepBFoundation, find us on Facebook at http://www.facebook.com/hepbfoundation or call 215-489-4900.

Contact: Sarah Larson at sarah(at)furiarubel(dot)com or 215-340-0480

Read the full story at http://www.prweb.com/releases/2014/01/prweb11488785.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Study: Higher Hepatitis C Infection During Acupuncture in Asian Americans; polyDNA Recommends That Doctors Prescribe Gene-Eden-VIR against HCV
2. FDA Advisory Committee Recommends Approval of Simeprevir for Combination Treatment of Genotype 1 Chronic Hepatitis C in Adult Patients
3. EU Should Better Prevent Citizens From Hepatitis, Says Liver Patients Organisation ELPA
4. Flagship Biosciences Introduces a New Technique for Measuring Fibrosis in Nonalcoholic Steatohepatitis
5. The Majority of Physicians that Treat Hepatitis C Virus (HCV) Have Begun "Warehousing" and Preparing Their HCV Patients for the Next Generation of HCV Treatments
6. SeraCare Introduces New Hepatitis C ACCUVERT Seroconversion Panels and Anti-Herpes ACCUSET Performance Panel
7. Benitec Selects University of California, San Diego as a Site for Phase I/II Clinical Trial of TT-034 in Patients with Hepatitis C Infections
8. Janssen Announces Data from Simeprevir in Hepatitis C Patients Will Be Presented at The International Liver Congress of the European Association for the Study of the Liver (EASL)
9. Comprehensive Global Testing Solutions for Novel Hepatitis C Therapeutics, New Webinar Hosted by Xtalks
10. A Phase IIa Interferon Free Combination Hepatitis C Trial of Simeprevir (TMC435) and TMC647055 Will Commence Shortly
11. Hepatitis B Therapeutics - Pipeline Assessment and Market Forecasts to 2019
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... Roka Bioscience, Inc. (NASDAQ: ROKA), a molecular diagnostics company focused ... pathogens,  today announced that Mary Duseau , CEO will ... March 29 at 9:50am ET. The conference will be held ... Roka Bioscience ... Roka Bioscience is a molecular diagnostics company focused ...
(Date:3/27/2017)... 2017 Infectex Ltd., a Russian portfolio company of Maxwell Biotech ... SQ109 added to the standard drug therapy regimen in patients with multidrug-resistant pulmonary tuberculosis ... ( USA ) and the US National Institutes of Health. ... ... Fund Logo ...
(Date:3/27/2017)... ... March 27, 2017 , ... PMG Research is pleased to ... presented by The Conference Forum in Boston on April 3-4, 2017. The CTC conference ... clinical trial outcomes and bring them closer to the patient. Clinical Trial Collaborations also ...
(Date:3/27/2017)... NEW YORK , March 27, 2017 /PRNewswire/ ... company developing novel therapies for neurodegenerative diseases, including ... confirmation that its application to list the Company,s ... been approved by The NASDAQ Stock Market, a ... of the listing, Neurotrope will ring the Opening Bell ...
Breaking Biology Technology:
(Date:3/6/2017)... MATEO, Calif. , March 6, 2017 /PRNewswire/ ... marketing and sales technology, today announced Predictive Sales ... solution for infusing actionable sales intelligence into Salesforce. ... to automatically enable their sales organizations with deep ... messages that allow for intelligent engagement. Predictive Sales ...
(Date:3/1/2017)... , March 1, 2017  Aware, Inc. (NASDAQ: AWRE), ... that Richard P. Moberg has resigned, effective ... and Chief Financial Officer and Treasurer of Aware citing ... serve as a member of the Board of Directors ... Aware,s co-Chief Executive Officer and co-President, General Counsel has ...
(Date:2/26/2017)... , Feb. 25, 2017  Securus Technologies, a ... solutions for public safety, investigation, corrections and monitoring, ... and Reentry. "Too often, too many ... and county jails are trying to tackle this ... and friends and family members. While significant steps are ...
Breaking Biology News(10 mins):